Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein, conserved | 0.003 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible lipoprotein LppD | 0.003 | 0.5 | 0.5 |
Echinococcus granulosus | MACRO domain containing protein 2 | 0.003 | 0.5 | 0.5 |
Mycobacterium ulcerans | lipoprotein LppD | 0.003 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.003 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.5 | 0.5 |
Echinococcus multilocularis | MACRO domain containing protein 2 | 0.003 | 0.5 | 0.5 |
Echinococcus multilocularis | MACRO domain containing protein 2 | 0.003 | 0.5 | 0.5 |
Echinococcus granulosus | MACRO domain containing protein 2 | 0.003 | 0.5 | 0.5 |
Trypanosoma cruzi | Macro domain containing protein, putative | 0.003 | 0.5 | 0.5 |
Trichomonas vaginalis | ganglioside induced differentiation associated protein, putative | 0.003 | 0.5 | 0.5 |
Trypanosoma brucei | Macro domain containing protein, putative | 0.003 | 0.5 | 0.5 |
Toxoplasma gondii | macro domain-containing protein | 0.003 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein, conserved | 0.003 | 0.5 | 0.5 |
Trypanosoma cruzi | Macro domain containing protein, putative | 0.003 | 0.5 | 0.5 |
Trichomonas vaginalis | ganglioside induced differentiation associated protein, putative | 0.003 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.003 | 0.5 | 0.5 |
Plasmodium falciparum | Appr-1-p processing domain protein | 0.003 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.003 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein, conserved | 0.003 | 0.5 | 0.5 |
Giardia lamblia | Protein LRP16 | 0.003 | 0.5 | 0.5 |
Trichomonas vaginalis | ganglioside induced differentiation associated protein, putative | 0.003 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Complex formation (functional) | = 18 % | Effect of the compound on cellular protein DNA complex formation(%) at 10 microM in comparison with etoposide | ChEMBL. | 1312601 |
Complex formation (binding) | = 18 % | Percentage of intracellular covalent DNA-topoisomerase II complexes formed | ChEMBL. | 12014968 |
IC50 (functional) | > 2.1 uM | Concentration required for 50% reduction in KB cell number after 3-day incubation | ChEMBL. | 1312601 |
ID50 (binding) | = 20 uM | Inhibition of human DNA Topoisomerase II | ChEMBL. | 1312601 |
ID50 (binding) | = 20 uM | Inhibition of human DNA Topoisomerase II | ChEMBL. | 1312601 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.